Frequency and disproportionality of reporting for second primary malignancies (SPMs) in different CAR T products. (A) Proportion of reports for each SPM (in high-level group terms) within each product, realtive to the number of AE reports in the respective product. (B) Absolute number of reports for each SPM (in high-level group terms) in CAR T products. (C) Disproportionality of reporting measured as the ROR, compared with non-CAR T drugs administered for the respective indication. Gray areas reflect insufficient number of reports (<3 reports) and thus ROR was not calculated. Green areas reflect significant ROR, defined as lower bound of the 95% CI of >1. Yellow areas reflect nonsignificant ROR signal. Axi, axicabtagene ciloleucel; Brexu, brexucabtagene autoleucel; Cilta, ciltacabtagene autoleucel; excl, excluding; HLGT, high-level group term; Ide, idecabtagene vicleucel; leuk, leukemia; Liso, lisocabtagene maraleucel; lymph, lymphoma; NEC, not elsewhere classified; Tisa, tisagenlecleucel.